needed effects
telbivudine
active ingredient
tyzeka
unwanted side effects
medical attention
telbivudine side effects
medical attention
body
medicine
side effects
health care professional
side effects
following side effects
telbivudine
active ingredient
tyzeka
clinical studies
most side effects
telbivudine
discontinuations
adverse events
telbivudine recipients
lamivudine recipients
common side effects
discontinuation of telbivudine
elevated creatine kinase
ck
nausea
diarrhea
fatigue
myalgia
myopathy
increased ck
telbivudine
active ingredient
tyzeka
treatment during clinical trials
weeks of treatment
telbivudine-treated patients
lamivudine-treated patients
grade
ck elevations
percent
telbivudine
lamivudine-treated patients
grade
ck elevations
most patients with ck elevations
symptoms
average recovery time
telbivudine-treated patients
lamivudine-treated patients
telbivudine-treated patients with grade
ck elevations
musculoskeletal side effect
lamivudine-treated patients
weeks of treatment
telbivudine-treated patients
grade
ck elevations
visits
baseline levels
cases of myopathy/myositis
telbivudine use
several weeks
months
following treatment initiation
ck
times uln
ck common
arthralgia
pain
myalgia
myopathy/myositis
presenting with muscular weakness
frequency
fibromyalgia
muscle strain
chest wall pain
noncardiac chest pain
chest discomfort
flank pain
muscle cramp
musculoskeletal chest pain
musculoskeletal pain
musculoskeletal discomfort
musculoskeletal stiffness
myofascial pain syndrome
neck pain
pain in extremity
tendernesspostmarketing reports
rhabdomyolysis
fatigue common
pyrexia frequency
malaise
vertigo
influenza
influenza-like symptoms
postprocedural pain
headache common
dizziness
insomnia
peripheral neuropathy
frequency
migraine
sinus headache
tension headachepostmarketing reports
paresthesia
hypoesthesia
alt
times baseline
ast
sgot
times baseline
alt
times uln
times baseline
i.
e.
acute hepatitis flare
alt
hepatitis b exacerbation
total bilirubin
times uln
frequency
lactic acidosis
steatosis
hypercholesterolemia
posttreatment exacerbations of hepatitis
lactic acidosis
steatosis
including
fatal cases
use of telbivudine
other nucleoside analogs
combination with other antiretroviral agents
incidence of alt flares
alt
times uln
times baseline
treatment arms in the first months
week
alt flares
telbivudine-treated patients
lamivudine-treated patients
posttreatment exacerbations of hepatitis
discontinuation of telbivudine
diarrhea
upper abdominal pain
nausea
abdominal pain
abdominal distension
dyspepsia
lipase
times uln uncommon
amylase
times uln
frequency
gastritis
sore throat
dry mouth
appetite
abdominal discomfort
lower abdominal pain
gastrointestinal pain
cough
pharyngolaryngeal pain frequency
upper
respiratory tract infection
nasopharyngitis
rash
frequency
acne
neutropenia
absolute neutrophil count
mm
thrombocytopenia
platelets
mm
postmarketing reports
lactic acidosis
patient reporting polyuria
receiving
ascites
polyuria
frequency
hematuria
irregular menstruation
side effects
fda
healthcare professional for medical advice
chills
cough
diarrhea
fever
general feeling of discomfort
illness
headache
joint pain
loss of appetite
muscle aches
pains
nausea
runny nose
shivering
sore throat
stomach pain
sweating
trouble with sleeping
unusual tiredness
weakness
vomiting
back pain
chest pain
difficulty with moving
muscle cramping
muscle stiffness
muscle tenderness
wasting
weakness
pain
pain in the extremity
swollen joints
burning feeling in the chest
stomach
indigestion
loose stools
stomach upset
tenderness in the stomach area
burning
crawling
itching
numbness
prickling
pins
needles
tingling feelings
dark-colored urine
decreased appetite
fast, shallow breathing
muscle pain
spasms
shortness of breath
sleepiness
body aches
pain
difficulty with breathing
ear congestion
loss of voice
nasal congestion
sneezing
stuffy nose
acid
sour stomach
belching
dizziness
heartburn
rash
sleeplessness
stomach discomfort
unable to sleep